Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system

Jennifer Lord, M. Mateo Paz Soldan, Jonathan Galli, Karen L. Salzman, Jacob Kresser, Rae Bacharach, L. Dana DeWitt, Julia Klein, John Rose, John Greenlee, Stacey L. Clardy

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To characterize patients with neurosarcoidosis within the University of Utah healthcare system, including demographics, clinical characteristics, treatment, and long-term outcomes. METHODS: We describe the clinical features and outcomes of patients with neurosarcoidosis within the University of Utah healthcare system (a large referral center for 10% of the continental United States by land mass). Patients were selected who met the following criteria: (1) at least one International Classification of Diseases Clinical Modification, 9th revision code 135 or International Classification of Diseases Clinical Modification, 10th revision code D86* (sarcoidosis) and (2) at least one outpatient visit with a University of Utah clinician in the Neurology Department within the University of Utah electronic health record. RESULTS: We identified 56 patients meeting the study criteria. Thirty-five patients (63%) were women, and most patients (84%) were white. Twelve patients (22%) met the criteria for definite neurosarcoidosis, 36 patients (64%) were diagnosed with probable neurosarcoidosis, and 8 patients (14%) were diagnosed with possible neurosarcoidosis. A total of 8 medications were used for the treatment of neurosarcoidosis. Prednisone was the first-line treatment in 51 patients (91%). Infliximab was the most effective therapy, with 87% of patients remaining stable or improving on infliximab. Treatment response for methotrexate and azathioprine was mixed, and mycophenolate mofetil and rituximab were the least effective treatments in this cohort. CONCLUSIONS: This is a comprehensive characterization of neurosarcoidosis within a single healthcare system at the University of Utah that reports long-term response to treatment and outcomes of patients with neurosarcoidosis. Our results suggest the use of infliximab as a first-line therapy for neurosarcoidosis.

Original languageEnglish (US)
JournalNeurology: Neuroimmunology and NeuroInflammation
Volume7
Issue number4
DOIs
StatePublished - Jul 1 2020

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system'. Together they form a unique fingerprint.

  • Cite this

    Lord, J., Paz Soldan, M. M., Galli, J., Salzman, K. L., Kresser, J., Bacharach, R., DeWitt, L. D., Klein, J., Rose, J., Greenlee, J., & Clardy, S. L. (2020). Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system. Neurology: Neuroimmunology and NeuroInflammation, 7(4). https://doi.org/10.1212/NXI.0000000000000743